Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Authors
Keywords
-
Journal
JACC-Heart Failure
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-05-21
DOI
10.1016/j.jchf.2023.05.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction
- (2023) Dejana Popovic et al. EUROPEAN JOURNAL OF HEART FAILURE
- Heart Failure With Preserved Ejection Fraction
- (2023) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The stratified win statistics (win ratio, win odds, and net benefit)
- (2023) Gaohong Dong et al. PHARMACEUTICAL STATISTICS
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
- (2022) Paul A. Heidenreich et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets
- (2022) Barry A Borlaug et al. CARDIOVASCULAR RESEARCH
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
- (2022) Mikhail N. Kosiborod et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin for heart failure according to body mass index: the DELIVER trial
- (2022) Carly Adamson et al. EUROPEAN HEART JOURNAL
- Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery
- (2022) Hidemi Sorimachi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of Heart Failure
- (2021) Véronique L. Roger CIRCULATION RESEARCH
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction
- (2021) Hidemi Sorimachi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality
- (2021) Frederik H. Verbrugge et al. EUROPEAN HEART JOURNAL
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
- (2021) Michael E. Nassif et al. NATURE MEDICINE
- Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity
- (2020) Yogesh N.V. Reddy et al. EUROPEAN JOURNAL OF HEART FAILURE
- Evaluation and management of heart failure with preserved ejection fraction
- (2020) Barry A. Borlaug Nature Reviews Cardiology
- Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study
- (2019) Yogesh N.V. Reddy et al. MAYO CLINIC PROCEEDINGS
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction
- (2019) Yogesh N.V. Reddy et al. JOURNAL OF CARDIAC FAILURE
- Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction
- (2018) Haider J. Warraich et al. Circulation-Heart Failure
- Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women
- (2017) Yau-Huei Lai et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
- (2016) Sanjiv J. Shah et al. CIRCULATION
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction
- (2016) Dalane W. Kitzman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle
- (2015) T. Scott Bowen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
- (2015) Margaret M. Redfield et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Failure With Preserved Ejection Fraction
- (2014) Kavita Sharma et al. CIRCULATION RESEARCH
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction
- (2013) Susan M. Joseph et al. Circulation-Heart Failure
- Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases
- (2013) Barry A. Borlaug EUROPEAN HEART JOURNAL
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- (2013) Frank Edelmann et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction
- (2013) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
- (2013) Walter J. Paulus et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial
- (2012) Thomas S. Rector et al. Circulation-Heart Failure
- Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction
- (2011) Markus Haass et al. Circulation-Heart Failure
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now